Bifalgorithm post · Research cancer 2025 · Detecting Minimal Residual Disease and Recurrence

Clinical Barriers

Clinical Barriers (Research cancer 2025 · Detecting Minimal Residual Disease and Recurrence) — "Although liquid biopsy has shown promise in enhancing current m…

Ideas in this flowchart

  • Liquid biopsy shows promise but faces barriers to routine clinical use.
  • It can enhance current methods of cancer detection and monitoring.
  • Challenges currently limit its routine clinical adoption.
  • Key barriers affect the adoption of circulating tumor DNA (ctDNA).
  • The amount of detectable material can vary.
  • Standardized protocols are lacking.
  • These barriers have been highlighted by Bartolomucci A et al. (2025), NPJ Precis Oncol, 9:84.
  • Continued research is needed to overcome these hurdles.
  • Overcoming them could unlock personalized cancer care and guided treatment.
Bifalgorithm
Sign up
Feed/

Clinical Barriers

No cover

Channel

Research cancer 2025

1 page

U
USR292600b83e2a
Ebook2w

"Although liquid biopsy has shown promise in enhancing current methods of cancer detection and monitoring, challenges remain that limit its routine clinical use (see Sidebar 55). Researchers have highlighted key barriers to ctDNA adoption, some of which include a variable amount of detectable material and lack of standardized protocols (1091)Bartolomucci A, et al. (2025) NPJ Precis Oncol, 9: 84.. Overcoming these hurdles through continued research will be essential to fully unlock the potential of liquid biopsies to personalize cancer care and guided treatment."

Flowchart preview
👍
0
0 comments0 shares

Sign in to view and post comments.